Corporation reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of $0.76 against the forecast of $0.74. Revenue also exceeded projections, ...

Bruker ’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and its ongoing portfolio transformation. Yet, the company’s operations face the wrath of excessive ...

All peptide samples were analyzed using a timsTOF Pro 2 mass spectrometer coupled with a nanoElute liquid chromatography system (Bruker Daltonik GmbH, Germany). Peptides were directly injected onto an ...

The samples were dried, crystallized on the target plate, and detected using timsTOF fleX MALDI2 (Bruker, Germany). Nucleic Acid Fragmentation Test Standard (8217028, Bruker) was used for instrument ...

Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share ...

Bruker, known for its focus on proteomics, might face a 0.6% revenue risk, with the assumption that its timsTOF line, priced at around $300,000 per instrument, accounts for 3% of total sales and ...